Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03717142 · ClinicalTrials.gov registry record · NA
Feasibility of the LUM Imaging System for Detection of Cancer to the Brain
A NA study, sponsored by Lumicell.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT03717142 is a NA study that was terminated before completion, run by Lumicell. The registered enrollment target is 4 participants.
The verdict
NCT03717142, a NA study, was terminated before completion, sponsored by Lumicell.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
The overall objective of this study is to assess the safety and efficacy of the LUM Imaging System in imaging primary and metastatic cancer in the brain. This includes selecting a dose to determine the initial efficacy of LUM015 for the molecular imaging of low-grade gliomas, glioblastomas and cancer masses that have metastasized to the brain.
Interventions
- COMBINATION_PRODUCT LUM Imaging System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-05-03 |
| Est. Completion | 2024-06-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03717142
The ClinicalTrials.gov registry entry for NCT03717142 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumicell, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LUM Imaging System is the first listed.
NCT03717142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03717142 about?
NCT03717142 is a clinical study titled "Feasibility of the LUM Imaging System for Detection of Cancer to the Brain". The overall objective of this study is to assess the safety and efficacy of the LUM Imaging System in imaging primary and metastatic cancer in the brain. This includes selecting a dose to determine the initial efficacy of LUM015 for the molecular imaging of low-grade gliomas, glioblastomas and cance...
What is the current status of trial NCT03717142?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2019-05-03. Estimated completion is 2024-06-14.
What interventions are being tested in trial NCT03717142?
The interventions under investigation include: LUM Imaging System (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03717142?
This trial is sponsored by Lumicell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.